The study, published in Bioengineering & Translational Medicine, comes from researchers at The University of Alabama who set out to strip away the confounding ingredients that have long plagued organoid modeling. Conventional glioblastoma organoids are typically made by embedding glioblastoma stem cells in animal-derived matrix hydrogels such as Matrigel and differentiating them with undefined serum supplements. Those ingredients provide structure, but they also mask the cells’ intrinsic capacity to fabricate their own microenvironment, introduce batch-to-batch variability, and make it nearly impossible to know whether any vessel-like structure observed in a dish formed because of the model or in spite of it. The new approach removes the exogenous matrix entirely, relying instead on controlled geometry and a sublethal level of fluid shear stress to coax the cells into organizing themselves.

To judge whether the resulting organoids were biologically faithful, the team first needed a rigorous clinical benchmark. They mined publicly available transcriptomic data from The Cancer Genome Atlas, curating a high-confidence subset of 35 patient cases spanning healthy brain tissue, low-grade glioma, and glioblastoma. Because the World Health Organization reclassified central nervous system tumors in 2021, shifting diagnosis toward molecular definitions, many older low-grade glioma cases would today be called glioblastoma. The researchers therefore subdivided the low-grade glioma cohort into molecular subgroups—those resembling normal tissue, those resembling glioblastoma, and a transitional group—effectively modernizing the clinical baseline. Principal component analysis revealed a clear developmental axis, and differential expression analysis defined a conserved glioma signature: upregulation of embryonic-like tissue growth programs and oxidative phosphorylation, paired with suppression of mature neuronal pathways, particularly GABA-ergic signaling. Crucially, network analysis identified VEGFA and fibronectin as central hubs linking vasculogenesis to collagen metabolism, confirming that glioma progression is underpinned by coordinated remodeling of neurovascular and matrix components.

With that baseline in hand, the team grew organoids from a patient-derived xenograft line called JX6, a classical-subtype glioblastoma carrying the amplified EGFR variant III mutation. Glioblastoma stem cells were first seeded into cell-repellent U-bottom plates to form spheroids of roughly 400 to 600 micrometers, then transferred to a stirred 100-milliliter bioreactor operating at a shear stress of about 0.5 pascals. No other media components, matrices, or scaffolds were added at any point. Under these conditions the organoids grew to four millimeters in diameter, and the researchers tracked their molecular development against the patient data across a unified five-stage scale. The comparison revealed a striking convergence: trajectories for capillary, venule, and large artery gene markers, along with astrocyte, fibroblast, and pericyte/smooth muscle cell signatures, all peaked in alignment with clinical benchmarks at the two-millimeter stage of organoid growth.

That two-millimeter milestone emerged as the heart of the study. Confocal imaging of organoids stained for the endothelial marker CD31 and the matrix proteins tenascin-C and fibronectin revealed a precise temporal cascade. Tiny 0.6-millimeter spheroids expressed essentially none of these markers. By one millimeter, tenascin-C—an anti-adhesive matrix protein associated with cell migration—appeared around the organoid core. At 1.5 millimeters, fibronectin was deposited peripherally and nascent endothelial clusters emerged. Only at two millimeters did fibronectin and CD31 significantly co-localize, indicating that the tumor cells first fabricate a fibronectin-rich scaffold and then recruit endothelial cells onto it—a matrix-primed sequence of vascular assembly that has been described in glioblastoma patients but rarely recapitulated in vitro.

The spatial architecture of the mature organoids proved equally faithful. Two-millimeter organoids displayed a distinct tri-zonal organization: an infiltrating rim rich in tenascin-C, a vascular-like area dominated by fibronectin and CD31, and a hypoxic, necrotic core. The rim’s thickness of roughly 153 to 180 micrometers sits just below the approximately 200-micrometer oxygen diffusion limit, defining a structurally coherent metabolic boundary. The vascular-like zone, spanning about 750 to 1,013 micrometers, contained the densest vessel branching and the tightest lumen spacing, echoing the weblike capillary beds of living tissue. Quantifying lumen sizes by minimum Feret diameter showed that most channels fell in the 5-to-10-micrometer range—the expected caliber of human capillaries—with larger structures matching arteriole and venule dimensions, and none exceeding 105 micrometers.

To test whether these structures were more than anatomical decoration, the researchers incubated organoids with a 3-kilodalton fluorescent dextran tracer, chosen because its size approximates temozolomide, the standard chemotherapy for glioblastoma. Multiphoton imaging of whole-mount cleared organoids showed clear tracer transport within capillary-like lumens of 9 to 12 micrometers in diameter, and the radial intensity gradients fit Fick’s second law of diffusion modeled in spherical coordinates, yielding an effective diffusion coefficient of about 0.15 square micrometers per second. That value is more than two orders of magnitude lower than measurements of 3-kilodalton dextran diffusion in the rat brain extracellular space, likely reflecting the densely packed protective rim, immature endothelial junctions, and the absence of internal hemodynamic shear stress. The authors note that human glioma tissue itself poses elevated diffusion resistance due to increased extracellular volume and tortuosity linked to tenascin-rich matrix deposition, so the comparison, while sobering, is not entirely discouraging.

The divergences that remain are informative rather than fatal. Organoids underexpressed proteoglycans involved in cell-matrix adhesion and diverged on arterial and large-vein markers, patterns the researchers attribute to the lack of controlled hemodynamic shear stress—the tangential force from blood flow that stabilizes endothelial identity in living vessels. Their proposed remedy is elegant: introduce internal perfusion via microfluidics at the one-to-1.5-millimeter stage, after the critical tenascin-C and fibronectin matrix has self-organized but before endothelial networks fully mature, while maintaining the existing bulk shear of roughly 0.5 pascals to support peripheral expansion. Such a system could push the organoids from modeling the anatomy of the tumor microenvironment toward a genuinely functional, human-centric platform for preclinical drug validation.

The therapeutic implications may be the most exciting part. Because the model reveals that glioblastoma stem cells actively prime their niche with an anti-adhesive-to-adhesive matrix switch—tenascin-C first, fibronectin second—to enable invasion and neovascularization, it nominates that scaffold as a drug target. High-throughput screening using these organoids could identify small molecules or antibodies that disrupt tenascin-C and fibronectin assembly, potentially weakening the tumor’s structural defenses and improving drug penetration across the blood-brain barrier. For a disease where nearly every experimental therapy has foundered on the same two obstacles—infiltration at the tumor margin and delivery across the vasculature—a reproducible, scaffold-free, human-derived model that recapitulates both processes autonomously represents a meaningful step forward. The organoids do not yet beat like a living brain, but they are, remarkably, building themselves.

Subject of Research: Matrix-free biomanufacturing of glioblastoma organoids that self-assemble neurovascular-like structures and extracellular matrix

Article Title: Exogenous matrix‐free biomanufacturing of glioblastoma organoids enables autonomous assembly of neurovascular‐like structures and extracellular matrix

Article References: Avera, A. D., Schnorbus, T. N., & Kim, Y. (2026). Exogenous matrix‐free biomanufacturing of glioblastoma organoids enables autonomous assembly of neurovascular‐like structures and extracellular matrix. Bioengineering & Translational Medicine, Article e70166. https://doi.org/10.1002/btm2.70166

Image Credits: AI Generated

DOI: 10.1002/btm2.70166

Keywords: glioblastoma, organoids, neurovascular unit, extracellular matrix, glioblastoma stem cells, tenascin-C, fibronectin, biomanufacturing, blood-brain barrier, drug screening, TCGA, bioreactor

Single-cell RNA sequencing has transformed biology by allowing researchers to measure the complete transcriptional activity of thousands of individual cells in a single experiment. This technology reveals extraordinary diversity within tissues, distinguishing cell types and even subtle cell states that bulk measurements would average away. However, scRNA-seq carries a fundamental limitation: during the dissociation process required to prepare samples, cells are physically separated from their tissue context. The resulting data describe what each cell is doing, but not where it was located. Spatial transcriptomics was developed precisely to solve this problem, preserving the spatial organization of cells within tissue sections while still capturing gene expression information. Yet even the most advanced spatial platforms typically profile fewer genes per cell or provide lower molecular resolution than dissociative single-cell methods, and most experiments capture only a single moment in time.

The new framework, developed by Mahdi Pursalim, Kaveh Kavousi, and Parisa Shooshtari, tackles the integration problem directly. The approach operates in two complementary stages. In the first stage, the method performs reference-based spatial deconvolution, a computational procedure that uses scRNA-seq data as a reference atlas to estimate which cell types are present in each spot or region of a spatial transcriptomics measurement. Because spatial platforms often measure mixtures of cells within each capture location, deconvolution is essential for untangling these mixed signals and recovering the underlying cellular composition. The second stage applies single-cell spatial mapping, transferring individual cells from the scRNA-seq dataset onto their most likely spatial positions within the tissue, guided by the gene expression similarities between the single-cell profiles and the spatial measurements.

What distinguishes this framework from previous integration efforts is its explicit treatment of time. The method is designed to work with time-series data—sets of scRNA-seq and spatial transcriptomics measurements collected at multiple, consecutive time points. By applying the deconvolution and mapping procedures independently at each time point and then comparing the results across consecutive stages, the framework quantifies how spatial cell-type distributions shift over the course of a biological process. These temporal changes are summarized using complementary abundance-weighted spatial descriptors, quantitative measures that capture both the proportion of each cell type and its spatial arrangement within the tissue. In parallel, the framework characterizes inferred cell-state dynamics by tracking changes in dominant cell-type assignments across consecutive time points, providing a computational estimate of how the state composition of the tissue evolves.

Recognizing that any computational method is only as trustworthy as its validation, the researchers subjected the spatial abundance component of their framework to rigorous simulation-based benchmarking. They generated synthetic spatial datasets with known, predefined cell-type compositions, using these simulated ground truths to quantitatively compare their approach against alternative spatial deconvolution and mapping methods. This evaluation strategy is critical in a field where real experimental data rarely come with complete knowledge of the true cellular makeup of every spatial location. The benchmarking results support the framework’s ability to recover simulated spatial cell-type abundance patterns, offering reassurance that the estimates it produces reflect genuine biological structure rather than computational artifacts.

To demonstrate the framework’s biological utility and generalizability, the team applied it to two systems at opposite ends of the biological spectrum: human glioblastoma organoids and embryonic chicken heart development. Glioblastoma organoids are laboratory-grown, three-dimensional structures derived from human cells that recapitulate key features of aggressive brain tumors, making them valuable models for studying cancer progression in a controlled setting. The framework revealed temporal patterns of spatial cell-type organization and inferred cell-state composition within these organoids that could not be detected through static analyses alone, offering a dynamic view of how the tumor-like cellular ecosystem reorganizes over time.

The second application, embryonic chicken heart development, represents one of the most dramatic examples of coordinated cellular behavior in biology. The heart forms through precisely choreographed movements of diverse cell populations, and disruptions to these processes underlie many congenital heart defects. When the researchers applied their framework to time-series data from developing chicken hearts, it captured temporal patterns in spatial cell-type redistribution and inferred cell-state dynamics that illuminate how the cellular architecture of this vital organ emerges during embryogenesis. Together, the two case studies—one disease-focused, one developmental—demonstrate that the framework is not tailored to a single biological context but can be applied broadly across systems where time-series single-cell and spatial data are available.

The authors are careful to frame their results with appropriate scientific caution, a nuance that matters for how the work should be interpreted. The framework captures what the researchers describe as spatiotemporal cell-type redistribution and inferred cell-state dynamics—computational measures derived from molecular data. These inferred quantities should be understood as descriptive computational measures rather than direct evidence of physical cell migration or lineage-validated state transitions. In other words, observing that the abundance of a cell type increases in a particular spatial region between two time points does not prove that cells physically traveled there; the change could also reflect differential proliferation, cell death, or changes in the sampling of the tissue. Similarly, apparent shifts in cell-state composition represent computational inferences rather than experimentally validated transitions of individual cells between states.

This caution reflects a broader truth about computational modeling of biological dynamics. Single-cell and spatial transcriptomics are destructive measurements—each sample is consumed in the process of profiling it—so reconstructing temporal behavior necessarily involves stitching together observations from different specimens assumed to represent the same underlying process. Despite this inherent limitation, the value of such models is considerable. They generate testable hypotheses about which cell populations move where, when specific state transitions occur, and how the spatial organization of tissues changes during development or disease. These hypotheses can then guide targeted follow-up experiments, such as live imaging or lineage tracing, that directly observe the behaviors the models predict.

The publication arrives at a moment when the experimental technologies underpinning the framework are advancing rapidly. Spatial transcriptomics platforms continue to increase in resolution, throughput, and affordability, and time-course studies combining scRNA-seq with spatial profiling are becoming increasingly common in developmental biology, cancer research, and regenerative medicine. What has lagged behind is the computational toolkit for integrating these data modalities across time in a principled, quantitative, and benchmarked way. By providing a broadly applicable framework with validated spatial abundance estimation, temporally resolved descriptors of cellular organization, and demonstrated performance across biologically distinct systems, the researchers offer the community a practical resource for systematic characterization of dynamic cellular behaviors. The work points toward a future in which the choreography of cells—their movements, positions, and transformations—can be reconstructed computationally from molecular snapshots, deepening understanding of how tissues build themselves, how tumors evolve, and how these processes might ultimately be modulated for therapeutic benefit.

The methodological choices behind the framework reflect practical constraints inherent to current spatial transcriptomics platforms. Reference-based deconvolution is necessary because many widely used spatial assays capture expression from groups of cells within each measured location, meaning the raw signal represents a mixture rather than a single cell. By anchoring this unmixing step to scRNA-seq references, the framework leverages the superior molecular resolution of dissociative profiling while retaining the positional information that spatial measurements provide. The complementary use of single-cell spatial mapping then adds a second layer of inference, assigning individual cells from the reference to plausible tissue positions based on expression similarity.

The benchmarking strategy deserves particular attention from readers evaluating the method. Simulation-based validation, in which synthetic spatial datasets are generated with known cell-type compositions serving as ground truth, allows quantitative comparison against alternative deconvolution and mapping approaches in a way that real tissue data cannot. Because no experimental measurement of a real tissue comes with a complete, verified inventory of every cell type at every location, simulations provide the only setting where estimation accuracy can be measured directly. The reported performance of the spatial abundance component against competing methods therefore offers a meaningful, if partial, assessment of reliability.

The two biological applications also illustrate the diversity of questions the framework can address. Glioblastoma organoids and the embryonic chicken heart differ not only in species and biological context but in the character of their cellular dynamics: one models the progressive reorganization of a tumor-like cellular ecosystem, while the other captures the choreographed emergence of organ architecture during embryogenesis. That a single computational pipeline can extract temporally resolved patterns of spatial cell-type organization and inferred cell-state composition from both systems suggests the approach is not dependent on tissue-specific assumptions, an important property for a tool intended for broad community use.

The authors’ framing of their results as descriptive computational measures rather than direct evidence of physical cell migration or lineage-validated state transitions is a notable feature of the work. Such interpretive restraint is uncommon and valuable in a field where language about cell movement can easily outpace what molecular snapshot data can actually demonstrate. The framework is published as open access under a Creative Commons license, and the article appeared as a citable, peer-reviewed accepted manuscript carrying a permanent DOI, with a final Version of Record to follow. The research was supported in part by the Children’s Health Research Institute and the Ontario Institute for Cancer Research.

Subject of Research: Integrative computational modeling of cell migration and tissue organization using time-series single-cell RNA sequencing and spatial transcriptomics data

Article Title: Systems-level modeling of cell migration using spatially-resolved single-cell data

Article References: Pursalim, M., Kavousi, K., & Shooshtari, P. (2026). Systems-level modeling of cell migration using spatially-resolved single-cell data. BMC Bioinformatics. https://doi.org/10.1186/s12859-026-06649-z

Image Credits: AI Generated

DOI: 10.1186/s12859-026-06649-z

Keywords: cell migration, spatial transcriptomics, single-cell RNA sequencing, spatiotemporal modeling, deconvolution, cell-state dynamics, glioblastoma organoids, chicken heart development, time-series analysis, computational biology, tissue organization, cell types

The core idea is to implant fluorescently labeled human glioblastoma organoids (GBOs) into organotypic human brain slices. This pairing allows malignant cells to invade within a realistic brain microenvironment while maintaining the genetic integrity and cytoarchitecture of both partners. In doing so, the model targets the long-distance communication concept that underlies glioblastoma as a “whole-brain” disease.

To visualize infiltration across the full range—from the initial contact region to single-cell dispersion—the workflow combines tissue expansion with light-sheet fluorescence microscopy. Light-sheet imaging provides high-resolution, three-dimensional views across thick samples, capturing the invasive front without compressing the biological context.

Technically, Core2Edge begins with brain slice preparation, typically taking about 4–6 hours depending on how many slices are handled. The GBOs are then prepared and cultured for roughly one day for initial maintenance before staining and transplantation into the slices. After implantation, a variable culture period of up to 10 days is used to allow invasion to progress to deeper regions.

Following imaging readiness, the samples are fixed for around 8 hours to stabilize tissue architecture for downstream microscopy. Once the GBOs are prepared, the protocol as a whole runs approximately 7–12 days, bridging organoid biology with slice-based invasion dynamics.

Because GBO-derived cells can be tracked fluorescently, researchers can quantify early infiltration steps and focus on cell–cell interactions at the tumor–microenvironment interface. The platform is also positioned for mechanistic studies of invasive progression and for evaluating how therapeutic candidates affect both core invasion and edge dissemination.

Importantly for translational research, Core2Edge supports drug screening and testing in a human-relevant context, potentially reducing dependence on animal experiments for questions tied to infiltration and transcriptional variability.

By enabling comprehensive mapping of infiltration and preserving heterogeneity, Core2Edge provides a structured route to interrogate glioblastoma’s spatial biology—connecting transcriptional states with where and how tumor cells spread.

Subject of Research: Human ex vivo glioblastoma infiltration model

Article Title: Core2Edge: a human glioblastoma organoid–brain slice model capturing infiltration and transcriptional heterogeneity from core to single-cell dispersion.

Article References: Melhem, A., Pregler, B.E.F., Rodriguez-Gatica, J.E. et al. Core2Edge: a human glioblastoma organoid–brain slice model capturing infiltration and transcriptional heterogeneity from core to single-cell dispersion. Nat Protoc (2026). https://doi.org/10.1038/s41596-026-01412-3

DOI: https://doi.org/10.1038/s41596-026-01412-3

Image Credits: AI Generated

Keywords: glioblastoma, organoids, organotypic brain slices, infiltration modeling, light-sheet fluorescence microscopy, ex vivo platform, drug screening, transcriptional heterogeneity